知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

1012 条记录 (耗时 0.039 秒)

    Mid-life vaccine and methods for boosting anti-mycobacterial immunity
    101.
    发明授权
    Mid-life vaccine and methods for boosting anti-mycobacterial immunity 有权
    中期疫苗和提高抗分枝杆菌免疫力的方法

    公开(公告)号：US07288261B2

    公开(公告)日：2007-10-30

    申请号：US10332512

    申请日：2001-07-10

    申请人： Ian M. Orme ,  John T. Belisle

    发明人： Ian M. Orme ,  John T. Belisle

    IPC分类号： A61K39/04 ,  A61K49/00 ,  A61K39/00

    CPC分类号： A61K39/04 ,  A61K39/00 ,  A61K2039/545 ,  A61K2039/57 ,  C07K14/35

    摘要： Vaccine compositions for boosting immunity to mycobacteria when administered in mid-life in a subject who has been vaccinated neonatally or in early childhood with BCG and in whom protective immunity has waned comprise one or more purified immunogenic proteins from Mycobacterium tuberculosis from a group of 30 proteins that stimulate T cell immunity and interferon-γ secretion. A preferred protein is Ag85A, the secreted product (SEQ ID NO:31) of the Rv3084c gene. Also disclosed are methods for boosting immunity in such BCG-vaccinated subjects comprising administering an effective amount of the above vaccine composition.

    摘要翻译： 用于增强免疫力的疫苗组合物，当在具有BCG的新生儿或早期儿童接种疫苗的受试者的中期使用时，对分枝杆菌的免疫力被提供，其中保护性免疫已经减少，包括来自一组30个蛋白质的结核分枝杆菌的一种或多种纯化的免疫原性蛋白质 刺激T细胞免疫和干扰素-γ分泌。 优选的蛋白质是Ag85A，Rv3084c基因的分泌产物（SEQ ID NO：31）。 还公开了在这种BCG接种的受试者中增强免疫力的方法，其包括施用有效量的上述疫苗组合物。

    Compositions and methods for treating malaria with cupredoxin and cytochrome
    105.
    发明申请
    Compositions and methods for treating malaria with cupredoxin and cytochrome 有权
    用氧还蛋白和细胞色素治疗疟疾的组合物和方法

    公开(公告)号：US20060251669A1

    公开(公告)日：2006-11-09

    申请号：US11436590

    申请日：2006-05-19

    申请人： Ananda Chakrabarty ,  Tapas Gupta ,  Tohru Yamada ,  Anita Chaudhari ,  Arsenio Fialho ,  Chang Hong

    发明人： Ananda Chakrabarty ,  Tapas Gupta ,  Tohru Yamada ,  Anita Chaudhari ,  Arsenio Fialho ,  Chang Hong

    IPC分类号： A61K38/44 ,  A61K39/00 ,  C12N9/02

    CPC分类号： C07K14/195 ,  A61K38/00 ,  C07K14/35 ,  C07K14/80 ,  C12N9/0006

    摘要： The present invention relates to cupredoxin and cytochrome and their use, separately or together, to inhibit the spread of parasitemia in mammalian red blood cells and other tissues infected by the malaria parasite, and in particular the parasitemia of human red blood cells by P. falciparum. The invention provides isolated peptides that are variants, derivatives or structural equivalents of cupredoxins or cytochrome c, and compositions comprising cupredoxins and/or cytochrome c, or variants, derivatives or structural equivalents thereof, that are useful for treating or preventing malaria infection in mammals. Further, the invention provides methods to treat mammalian patients to prevent or inhibit the growth of malarial infection in mammals. The invention also provides methods to prevent the growth of malaria infection in insect vectors.

    摘要翻译： 本发明涉及氧还蛋白和细胞色素及其分别或一起用于抑制哺乳动物红细胞和其他感染疟原虫的组织中寄生虫血症的扩散，特别是恶性疟原虫人红细胞的寄生虫血症 。 本发明提供了分离的肽，其是铜氧还蛋白或细胞色素c的变体，衍生物或结构等同物，以及可用于治疗或预防哺乳动物疟疾感染的铜氧还蛋白和/或细胞色素c或其变体，衍生物或其结构等同物的组合物。 此外，本发明提供了治疗哺乳动物患者预防或抑制哺乳动物疟疾感染生长的方法。 本发明还提供了防止昆虫载体中疟疾感染生长的方法。

    Abundant extracellular products and methods for their production and use
    108.
    发明申请
    Abundant extracellular products and methods for their production and use 审中-公开

    公开(公告)号：US20060182754A1

    公开(公告)日：2006-08-17

    申请号：US11334951

    申请日：2006-01-18

    申请人： Marcus Horwitz ,  Gunter Harth

    发明人： Marcus Horwitz ,  Gunter Harth

    IPC分类号： A61K39/02 ,  C07H21/04 ,  C12N15/74 ,  C12N1/21 ,  C07K14/35

    CPC分类号： C07K14/35 ,  A61K39/04 ,  A61K2039/53

    摘要： Vaccines based on one or more combinations of majorly abundant extracellular products of pathogens and methods for their use and production are presented. The most prevalent or majorly abundant extracellular products of a target pathogen are selected irrespective of their absolute molecular immunogenicity and used as vaccines to stimulate a protective immune response in mammalian hosts against subsequent infection by the target pathogen. The majorly abundant extracellular products may be characterized and distinguished by their respective N-terminal amino acid, amino acid, or DNA sequences. As the vaccines may comprise different combinations of the extracellular products, subunits thereof, or encoding nucleic acids, a broad range of effective immunotherapeutic compositions are provided by the present invention. In addition to other infectious agents, the vaccines so produced can be used to stimulate an effective immune response against intracellular pathogens and in particular Mycobacterium tuberculosis.

    Desaturase antigen of mycobacterium tuberculosis
    110.
    发明授权
    Desaturase antigen of mycobacterium tuberculosis 失效
    结核分枝杆菌的去饱和酶抗原

    公开(公告)号：US07071320B2

    公开(公告)日：2006-07-04

    申请号：US10368433

    申请日：2003-02-20

    申请人： Mary Jackson ,  Brigitte Gicquel

    发明人： Mary Jackson ,  Brigitte Gicquel

    IPC分类号： C07H21/04 ,  C07H21/02 ,  C12Q1/68

    CPC分类号： C12N9/0083 ,  A61K39/00 ,  C07K14/35 ,  C07K16/1289 ,  G01N33/5695 ,  G01N2333/35 ,  G01N2469/20

    摘要： The use of genetic methodology based on the fusion of the proteins with the alcaline phosphatase (Lim et al., 1995) has allowed the isolation of a new exported protein of M. tuberculosis. In the present article, first of all the isolation of a gene encoding this exported protein called DES is described as well as its characterization and its distribution among the different mycrobacterial species. It is notably shown that the protein has in its primary sequence amino acids only found at the level of active sites of enzymes of class II diiron-oxo proteins family. Among the proteins of this family, DES protein of M. tuberculosis does not present significative homologies with stearoyl ACP desaturases. Secondly, the antigenic feature of this protein has been studied. For this, DES protein of M. tuberculosis has been overexpressed in E. coli under recombinant and purified protein form from this bacterium. The reactivity of tuberculous patients sera infected by M. tuberculosis or M. bovis against DES protein in Western blot experimentations has been tested. 100% of the tested patients did recognize the protein. The intensity of the antibody response against DES protein measured by ELISA of tuberculous patients sera compared with the one relating to sera patients suffering from other pathologies show that there is a significative difference between the intensity of the antibody responses of these two categories of patients. Accordingly, DES protein is a potentially interesting tool for the tuberculosis serodiagnostic.

    摘要翻译： 基于蛋白质与碱性磷酸酶融合的遗传方法的使用（Lim et al。，1995）允许分离新出现的结核分枝杆菌蛋白。 在本文中，首先描述了编码这种出口的蛋白质的基因的分离，称为DES，以及其在不同的细菌物种之间的表征及其分布。 显着地表明，蛋白质在其初级序列中仅在II型二铁 - 氧代蛋白家族的酶的活性位点的水平上发现氨基酸。 在该家族的蛋白质中，结核分枝杆菌的DES蛋白质与硬脂酰ACP去饱和酶不具有显着的同源性。 其次，研究了该蛋白的抗原特征。 为此，结核分枝杆菌的DES蛋白已经在该细菌中以重组和纯化的蛋白质形式在大肠杆菌中过表达。 已经测试了在结核分枝杆菌感染结核分枝杆菌或牛分枝杆菌对Western印迹实验中对DES蛋白的反应性。 100％的测试患者确实识别蛋白质。 通过ELISA测定结核病患者血清抗体对DES蛋白的抗体强度与与其他病理学血清相关的抗体反应强度显示，这两类患者的抗体反应强度存在显着性差异。 因此，DES蛋白质是结核病血清诊断的潜在有趣工具。